The Disintegration and Dissolution of Nabumetone Dispersible Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Disintegration and Dissolution of Nabumetone Dispersible Tablets
Nabumetone was complexed with β-cyclodextrin, and a 23 factorial design was used to prepare dispersible tablets containing the drug or its complex.The authors analyzed the effects of complexation as well as the levels of ammonium bicarbonate and crospovidone on tablet wetting time (WT), disintegration time (DT), and percent dissolution efficiency at 60 min (%DE60).


Pharmaceutical Technology


7. B. Hoener, and L.Z. Benet, "Factors Influencing Drug Absorption and Drug Bioavailability," in Modern Pharmaceutics, G.S. Banker and C.T. Rhodes. Eds. (Marcel Dekker Inc., New York, 3rd ed., 1996), pp. 121-154.

8. H.M. Abdou, "Methods for Enhancement of Bioavailability" in Dissolution, Bioavailability and Bioequivalence, A. Gennaro et al., Eds. (Mack Publishing Company, Easton, Pennsylvania, 1989), pp. 455–476.

9. "Nabumetone" in United States Pharmacopeia 27 (United States Pharmacopeial Convention Inc., Rockville, MD, Asian edition. 2004), pp. 1268.

10. G. Zingone, and I. Rubessa, "Preformulation Studies of the Inclusion Complex Warfarin-β-Cyclodextrin," Int. J. Pharm. 291, 3–10, (2005).

11. S. Tommasini et al., "Impovement in Solubility and Dissolution Rate of Flavonoids by Complexation with β-Cyclodextrin," J. Pharm. Biomed. Anal. 35, 379–387 (2004).

12. S. Rawat and S.K. Jain, "Solubility Enhancement of Celecoxib using β-Cyclodextrin Inclusion Complexes," Eur. J. Pharm. Biopharm. 57, 263–267 (2004).

13. X. Wen et al., "Preparation and Study the 1:2 Inclusion Complex of Carvedilol with b-Cyclodextrin," J. Pharm. Biomed. Anal. 34, 517–532 (2004).

14. A.M. Saetern et al., "Effect of Hydroxypropyl-b-Cyclodextrin-Complexation and pH on Solubility of Camptothecin," Int. J. Pharm. 284, 61–68 (2004).

15. "Factors Influence Studies," in Pharmaceutical Experimental Design, G.A. Lewis, D. Mathieu, and R. Phan-Tan-Luu, Ed. (Marcel Dekker Inc, New York, 1999), pp. 79 –150.

16. M. Gohel et al., "Formulation Design and Optimization of Mouth Dissolve Tablets of Nimesulide using Vaccum Drying Technique," AAPS PharmSciTech 5, Article 36, (2006).

17. "Disintegration Test" in Pharmacoepia of India (Controller of Publications, Ministry of Health and Family Welfare, New Delhi, 4th ed., 1996), pp. A–80.

18. S. Schiemeier, and P.C. Schmidt, "Fast Dispersible Ibuprofen Tablets," Eur. J. Pharm. Sci. 15, 295-305, (2002).

19. "Tablets" in Pharmacoepia of India (Controller of Publications, Ministry of Health and Family Welfare, New Delhi, 4th ed., 1996), pp. 734–736.

20. G.S. Banker GS and N.R. Anderson, "Tablets," in The Theory and Practice of Industrial Pharmacy, L. Lachman, H.A. Lieberman, and J.L. Kanig, Ed. (Varghese Publishing House, 3rd ed., Mumbai, India, 1991), pp. 293–345.

21. K.A. Khan, "The Concept of Dissolution Efficiency," J. Pharm. Pharmacol. 27, 48–49 (1975).

22. V.J. Stella and R.A. Rajewski, "Cyclodextrins: Their Future in Drug Formulation and Delivery," Pharm. Res. 14, 556–567 (1997).

23. L.S. Koester et al, "Influence of b-Cyclodextrin Complexation on Carbamazepine Release from Hydroxypropyl Methylcellulose Matrix Tablets," Eur. J. Pharm. Biopharm. 55, 85–91 (2003).

24. K.S. Aithal, N. Udupa, and K.K. Sreenivasan, "Physicochemical Properties of Drug–Cyclodextrin Complexes," Indian Drugs 32, 293–305 (1995).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here